File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: A meta-analysis

TitleEffects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: A meta-analysis
Authors
KeywordsBazett's correction
meta-analysis
QT interval
Second-generation antipsychotics
Issue Date2011
PublisherSage Publications Ltd.. The Journal's web site is located at http://jop.sagepub.com
Citation
Journal Of Psychopharmacology, 2011, v. 25 n. 5, p. 646-666 How to Cite?
AbstractThe use of second-generation antipsychotics (SGAs) for the treatment of schizophrenia has surged worldwide. Amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, sertindole and ziprasidone have now been commonly prescribed. Their effects on QT interval differ but evidence remains sparse and mostly inconclusive. Since prolongation of heart-rate corrected QT interval has been implicated as an useful surrogate marker to predict drug-related cardiac mortality and pro-arrhythmic potentials, it is timely and necessary to compare the effects of Bazett's corrected QT interval (QT Bc) prolongation for the commonly prescribed SGAs. A meta-analysis was conducted according to suggestions by the Quality of Reporting of Meta-analysis group with literature identified using various databases and augmented with hand-searching to assess the magnitude and risk on QT Bc prolongation by these seven SGAs for treatments in adult subjects with schizophrenia. Because of incomplete QT Bc data reporting, quetiapine could not be assessed by the meta-analytical approach in this study. Aripiprazole was the only SGA associated with both statistically significant lower risk and mean change in QT Bc, with sertindole giving a statistically significant worsening effect on mean QT Bc. Other analyses did not demonstrate any statistically significant pooled effects for the studied SGAs, neither on the magnitude over mean or mean change, nor the risk on QT Bc prolongation. © 2011 The Author(s).
Persistent Identifierhttp://hdl.handle.net/10722/135419
ISSN
2015 Impact Factor: 3.637
2015 SCImago Journal Rankings: 1.746
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChung, AKen_HK
dc.contributor.authorChua, SEen_HK
dc.date.accessioned2011-07-27T01:34:55Z-
dc.date.available2011-07-27T01:34:55Z-
dc.date.issued2011en_HK
dc.identifier.citationJournal Of Psychopharmacology, 2011, v. 25 n. 5, p. 646-666en_HK
dc.identifier.issn0269-8811en_HK
dc.identifier.urihttp://hdl.handle.net/10722/135419-
dc.description.abstractThe use of second-generation antipsychotics (SGAs) for the treatment of schizophrenia has surged worldwide. Amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, sertindole and ziprasidone have now been commonly prescribed. Their effects on QT interval differ but evidence remains sparse and mostly inconclusive. Since prolongation of heart-rate corrected QT interval has been implicated as an useful surrogate marker to predict drug-related cardiac mortality and pro-arrhythmic potentials, it is timely and necessary to compare the effects of Bazett's corrected QT interval (QT Bc) prolongation for the commonly prescribed SGAs. A meta-analysis was conducted according to suggestions by the Quality of Reporting of Meta-analysis group with literature identified using various databases and augmented with hand-searching to assess the magnitude and risk on QT Bc prolongation by these seven SGAs for treatments in adult subjects with schizophrenia. Because of incomplete QT Bc data reporting, quetiapine could not be assessed by the meta-analytical approach in this study. Aripiprazole was the only SGA associated with both statistically significant lower risk and mean change in QT Bc, with sertindole giving a statistically significant worsening effect on mean QT Bc. Other analyses did not demonstrate any statistically significant pooled effects for the studied SGAs, neither on the magnitude over mean or mean change, nor the risk on QT Bc prolongation. © 2011 The Author(s).en_HK
dc.languageengen_US
dc.publisherSage Publications Ltd.. The Journal's web site is located at http://jop.sagepub.comen_HK
dc.relation.ispartofJournal of Psychopharmacologyen_HK
dc.rightsJournal of Psychopharmacology. Copyright © Sage Publications Ltd..-
dc.subjectBazett's correctionen_HK
dc.subjectmeta-analysisen_HK
dc.subjectQT intervalen_HK
dc.subjectSecond-generation antipsychoticsen_HK
dc.subject.meshAntipsychotic Agents - adverse effects - pharmacology - therapeutic use-
dc.subject.meshDatabases, Factual-
dc.subject.meshLong QT Syndrome - chemically induced-
dc.subject.meshRisk-
dc.subject.meshSchizophrenia - drug therapy-
dc.titleEffects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: A meta-analysisen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0269-8811&volume=25&issue=5&spage=646&epage=666&date=2011&atitle=Effects+on+prolongation+of+Bazett%27s+corrected+QT+interval+of+seven+second-generation+antipsychotics+in+the+treatment+of+schizophrenia:+a+meta-analysis-
dc.identifier.emailChua, SE: sechua@hku.hken_HK
dc.identifier.authorityChua, SE=rp00438en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1177/0269881110376685en_HK
dc.identifier.pmid20826552en_HK
dc.identifier.scopuseid_2-s2.0-79955445368en_HK
dc.identifier.hkuros187406en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79955445368&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume25en_HK
dc.identifier.issue5en_HK
dc.identifier.spage646en_HK
dc.identifier.epage666en_HK
dc.identifier.eissn1461-7285-
dc.identifier.isiWOS:000289768000005-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridChung, AK=36871926600en_HK
dc.identifier.scopusauthoridChua, SE=7201550427en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats